Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: A 4-week, randomized, double-blind, placebo-controlled clinical trial

Depression Research and Treatment

Volumn 2014, Issue , 2014, Pages

  Ghanizadeh, Ahmad ^a,b,c,d   Omranisigaroodi, Motahhar ^a   Javadpour, Ali ^a   Dabbaghmanesh, Mohammad Hossein ^e   Shafiee, Sara ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920593124     PISSN: 20901321     EISSN: 2090133X     Source Type: Journal    
DOI: 10.1155/2014/730505     Document Type: Article

References (27)

1. C. A. Janney, Fagiolini A., H. A. Swartz et al., "Are adults with bipolar disorder active Objectively measured physical activity and sedentary behavior using accelerometry," Journal of Affective Disorders, vol. 152-154, pp. 498-504, 2013.
2. F. A. Gomes, K. M. Almeida, P. V. Magalhães et al., "Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder," Revista Brasileira de Psiquiatria, vol. 35, no. 2, pp. 126-130, 2013.
3. G. Maina, E. Bechon, S. Rigardetto, and V. Salvi, "General medical conditions are associated with delay to treatment in patients with bipolar disorder," Psychosomatics, vol. 54, no. 5, pp. 437-442, 2013.
4. D. J. Lang, A. M. Barr, and R. M. Procyshyn, "Management of medication-related cardiometabolic risk in patients with severe mental illness," Current Cardiovascular Risk Reports, vol. 7, no. 4, pp. 283-287, 2013.
5. J. D. Brown, A. Barrett, E. Caffery et al., "Medication continuity among medicaid beneficiaries with Schizophrenia and bipolar disorder," Psychiatric Services, vol. 64, no. 9, pp. 878-885, 2013.
6. D. Vancampfort, K. Vansteelandt,C.U.Correll et al., "Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-Analysis of prevalence rates and moderators," The American Journal of Psychiatry, vol. 170, no. 3, pp. 265-274, 2013.
7. C. Andrade, Primary Prevention of Cardiovascular Events in Patients with Major Mental Illness: A Possible Role for Statins, Bipolar Disorder, 2013.
8. C. Crump, K. Sundquist, M. A. Winkleby, and J. Sundquist, "Comorbidities and mortality in bipolar disorder: a Swedish national cohort study," JAMA Psychiatry, vol. 70, no. 9, pp. 931-939, 2013.
9. J.Westman, J. Hällgren, K.Wahlbeck, D. Erlinge, L. Alfredsson, and U. Osby, "Cardiovascular mortality in bipolar disorder: A population-based cohort study in Sweden," BMJ Open, vol. 3, no. 4, Article ID e002373, 2013.
10. T. M. Laursen, K.Wahlbeck, J. Hällgren et al., "Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in theNordic countries," PLoS ONE, vol. 8, no. 6,Article ID e67133, 2013.
11. J.Klawitter, I. Zafar, A. T. Pennington et al., "Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease," BMC Nephrology, vol. 14, no. 1, article 165, 2013.
12. A. Kumar, N. Sharma, A. Gupta, H. Kalonia, and J. Mishra, "Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms," Brain Research, vol. 1471, pp. 13-22, 2012.
13. P. A. Reis, V. Estato, T. I. da Silva et al., "Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria," PLoS Pathogens, vol. 8, no. 12, Article ID e1003099, 2012.
14. T. C. B. Piermartiri, C. P. Figueiredo, D. Rial et al., "Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid- 1?40 administration in mice: evidence for dissociation between cognitive deficits and neuronal damage," Experimental Neurology, vol. 226, no. 2, pp. 274-284, 2010.
15. A. Parihar, M. S. Parihar, W. J. Zenebe, and P. Ghafourifar, "Statins lower calcium-induced oxidative stress in isolated mitochondria,"Human and Experimental Toxicology, vol. 31,no. 4, pp. 355-363, 2012.
16. B. Pfaffenseller, G. R. Fries, B. Wollenhaupt-Aguiar et al., "Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder," Expert Review of Neurotherapeutics, vol. 13, no. 7, pp. 827-842, 2013.
17. M. Berk, F. Kapczinski, A. C. Andreazza et al., "Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors," Neuroscience and Biobehavioral Reviews, vol. 35, no. 3, pp. 804-817, 2011.
18. A. Ghanizadeh andM. Berk, "Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia," Medical Gas Research, vol. 3, no. 1, p. 11, 2013.
19. M. Leboyer, I. Soreca, J. Scott et al., "Can bipolar disorder be viewed as a multi-system inflammatory disease" Journal of Affective Disorders, vol. 141, no. 1, pp. 1-10, 2012.
20. A. Ghanizadeh and A. Hedayati, "Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial," Depress Anxiety, vol. 30, no. 11, pp. 1084-1088, 2013.
21. I. Mansi, C. R. Frei, M. J. Pugh, and E. M. Mortensen, "Psychologic disorders and statin use: a propensity score-matched analysis," Pharmacotherapy, vol. 33, no. 6, pp. 615-626, 2013.
22. A. Lustman, S. Nakar, A. D. Cohen, and S. Vinker, "Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study," Prostate Cancer and Prostatic Diseases, vol. 17, no. 1, pp. 6-9, 2014.
23. J. E. Berner, "Statins can produce ataxia in bipolar disorder: two case reports," Journal of Clinical Psychiatry, vol. 71, no. 3, article 359, 2010.
24. R. C. Young, J. T. Biggs, V. E. Ziegler, and D. A.Meyer, "A rating scale for mania: reliability, validity and sensitivity," The British Journal of Psychiatry, vol. 133, no. 11, pp. 429-435, 1978.
25. I. Pacchiarotti, D. J. Bond, R. J. Baldessarini et al., "The International Society for Bipolar Disorders (ISBD) Task-Force report on antidepressant use in bipolar disorders,"TheAmerican Journal of Psychiatry, vol. 170, no. 11, pp. 1249-1262, 2013.
26. M. A. Omar, J. P. Wilson, and T. S. Cox, "Rhabdomyolysis and HMG-CoA reductase inhibitors," Annals of Pharmacotherapy, vol. 35, no. 9, pp. 1096-1107, 2001.
27. A. Ghanizadeh, Z. Rezaee, S. Dehbozorgi, M. Berk, and S. Akhondzadeh, "Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial," Psychiatry Research, 2014.